4.1 Review

Treating multiple sclerosis with monoclonal antibodies: a 2013 update

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Immunology

Treatment of multiple sclerosis with Anti-CD20 antibodies

Barbara Barun et al.

CLINICAL IMMUNOLOGY (2012)

Review Immunology

IL-17: A new actor in IFN-driven systemic autoimmune diseases

Aurelie Ambrosi et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2012)

Review Clinical Neurology

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Lisa Costelloe et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)

Review Rheumatology

Progressive multifocal leukoencephalopathy in autoimmune diseases

Elisabeth Palazzo et al.

JOINT BONE SPINE (2012)

Article Neurosciences

Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification

A. Laroni et al.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)

Letter Clinical Neurology

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

I. Ayzenberg et al.

JOURNAL OF NEUROLOGY (2012)

Article Clinical Neurology

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy

Remy Phan-Ba et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)

Article Clinical Neurology

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

Grant A. Hill-Cawthorne et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)

Review Clinical Neurology

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab

B. K. Kleinschmidt-DeMasters et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)

Article Clinical Neurology

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

L. Daelman et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Article Clinical Neurology

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

Sebastian Jander et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Review Clinical Neurology

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Per Soelberg Sorensen et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Editorial Material Clinical Neurology

SEVERE RELAPSES UNDER FINGOLIMOD TREATMENT PRESCRIBED AFTER NATALIZUMAB

Diego Centonze et al.

NEUROLOGY (2012)

Editorial Material Clinical Neurology

NATALIZUMAB-ASSOCIATED PML IDENTIFIED IN THE PRESYMPTOMATIC PHASE USING MRI SURVEILLANCE

Nicholas F. Blair et al.

NEUROLOGY (2012)

Editorial Material Clinical Neurology

THE EARLIER, THE SMALLER, THE BETTER FOR NATALIZUMAB-ASSOCIATED PML: IN MRI VIGILANCE VERITAS?

Remy Phan-Ba et al.

NEUROLOGY (2012)

Editorial Material Clinical Neurology

LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL

Valerie Rigau et al.

NEUROLOGY (2012)

Article Clinical Neurology

Impairment of JCV-specific T-cell response by corticotherapy

Caroline Antoniol et al.

NEUROLOGY (2012)

Review Clinical Neurology

The evidence for a role of B cells in multiple sclerosis

G. Disanto et al.

NEUROLOGY (2012)

Article Medicine, General & Internal

Fingolimod for Multiple Sclerosis

Daniel Pelletier et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Clinical Neurology

Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria

Chris H. Polman et al.

ANNALS OF NEUROLOGY (2011)

Article Clinical Neurology

Natalizumab and Impedance of the Homing of CD34+ Hematopoietic Progenitors

Christian Saure et al.

ARCHIVES OF NEUROLOGY (2011)

Review Oncology

Development of anti-CD20 therapy for multiple sclerosis

Beatrix Bartok et al.

EXPERIMENTAL CELL RESEARCH (2011)

Review Pharmacology & Pharmacy

The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis

Ithamar Heber Brinkman et al.

EXPERT OPINION ON DRUG SAFETY (2011)

Review Clinical Neurology

Treating multiple sclerosis with natalizumab

Pietro Iaffaldano et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)

Article Clinical Neurology

CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment

Giovanni Frisullo et al.

MULTIPLE SCLEROSIS JOURNAL (2011)

Article Clinical Neurology

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

I. L. Tan et al.

NEUROLOGY (2011)

Article Clinical Neurology

Natalizumab Dosage Suspension: Are We Helping or Hurting?

Timothy W. West et al.

ANNALS OF NEUROLOGY (2010)

Article Clinical Neurology

Anti-JC Virus Antibodies: Implications for PML Risk Stratification

Leonid Gorelik et al.

ANNALS OF NEUROLOGY (2010)

Review Clinical Neurology

Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis

Edward J. Fox

EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)

Review Clinical Neurology

Treating multiple sclerosis with monoclonal antibodies: a 2010 update

Mathias Buttmann

EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)

Editorial Material Clinical Neurology

Anticipated benefits and surprising effects of daclizumab in multiple sclerosis

Olaf Stuve et al.

LANCET NEUROLOGY (2010)

News Item Biotechnology & Applied Microbiology

Abbott outbids Biogen for Facet's multiple sclerosis antibody

Cormac Sheridan

NATURE BIOTECHNOLOGY (2010)

Editorial Material Clinical Neurology

Can we get rid of neutralizing antibodies against interferon-β?

M. Buttmann et al.

EUROPEAN JOURNAL OF NEUROLOGY (2009)

Article Biotechnology & Applied Microbiology

The role of natalizumab in hematopoietic stem cell mobilization

Frank Neumann et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2009)

Review Oncology

The late adverse events of rituximab therapy - rare but there!

Ron Ram et al.

LEUKEMIA & LYMPHOMA (2009)

Review Rheumatology

CD19: a promising B cell target for rheumatoid arthritis

Thomas F. Tedder

NATURE REVIEWS RHEUMATOLOGY (2009)

Article Clinical Neurology

Induction of systemic TNFα in Natalizumab-treated multiple sclerosis

M. Khademi et al.

EUROPEAN JOURNAL OF NEUROLOGY (2008)

Article Clinical Neurology

Treating multiple sclerosis with monoclonal antibodies

Mathias Buttmann et al.

Expert Review of Neurotherapeutics (2008)

Letter Medicine, General & Internal

Anti-glomerular basement membrane disease after alemtuzumab

Menna R. Clatworthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Medicine, General & Internal

Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis

Alasdair J. Coles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Medicine, General & Internal

B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Review Immunology

Colony-stimulating factors in inflammation and autoimmunity

John A. Hamilton

NATURE REVIEWS IMMUNOLOGY (2008)

Article Multidisciplinary Sciences

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models

Haruhisa Inoue et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Article Neurosciences

LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury

Benxiu Ji et al.

MOLECULAR AND CELLULAR NEUROSCIENCE (2006)

Article Clinical Neurology

Immune surveillance in multiple sclerosis patients treated with natalizumab

O Stüve et al.

ANNALS OF NEUROLOGY (2006)

Article Multidisciplinary Sciences

Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

B Bielekova et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

Article Clinical Neurology

The window of therapeutic opportunity in multiple sclerosis

AJ Coles et al.

JOURNAL OF NEUROLOGY (2006)

Article Clinical Neurology

Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria

CH Polman et al.

ANNALS OF NEUROLOGY (2005)

Article Medicine, General & Internal

Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

A Langer-Gould et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

G Van Assche et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Neurosciences

LINGO-1 negatively regulates myelination by oligodendrocytes

S Mi et al.

NATURE NEUROSCIENCE (2005)

Article Neurosciences

LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex

S Mi et al.

NATURE NEUROSCIENCE (2004)